Eli Lilly's CEO on GLP-1s, Future of Health, and AI

Summary

Eli Lilly's journey from its founding in eighteen seventy-six to becoming the first healthcare company to reach a trillion dollar valuation is marked by groundbreaking innovations like insulin and Prozac, with GLP-1 therapies now driving its current growth. The company believes GLP-1 drugs, such as Zepbound and Mounjaro, represent a transformative technology, potentially more impactful than AI, due to their near universal effectiveness in weight loss and their ability to positively affect metabolic and cardiovascular health. Beyond obesity, this class of drugs is showing promise in reducing inflammation, potentially alleviating conditions like arthritis, and may even help mitigate addiction and reduce the risk of certain cancers. While the high cost of these medications is a significant barrier, Eli Lilly is actively working to increase accessibility through programs like Lily Direct, which offers lower prices by bypassing traditional healthcare channels, and new agreements with state Medicaid programs and Medicare. The company is investing heavily in manufacturing capacity to meet demand and expects prices to fall further with increased competition and supply. Regarding AI, while Lilly uses it for knowledge consolidation and literature searches, the CEO emphasizes that true drug discovery still requires extensive experimentation and human oversight, viewing AI's significant impact in this field as a longer-term prospect, perhaps a ten-year arc. He also cautions against the unregulated online market for 'peptides,' stressing the importance of rigorous scientific testing and FDA approval for safety and efficacy. Looking ahead, Lilly is focused on expanding the applications of its science and on enabling millions of people to live healthier lives, aiming for volume and return rather than just maximizing price.